Why the study?
Traditional delivery of antiresorptive drugs for osteoporosis lacks specific biodistribution and may cause adverse effects.
Engineered plant virus nanoparticles targeting RANK Motif2/3 show promise as a targeted therapy for osteoporotic bone loss in preclinical models.
Answers are grounded in this paper and cite their sources.
May reduce off-target effects in osteoporosis; hypothesis-generating for targeted therapies.
Osteoporosis is a systemic skeletal disorder characterized by excessive osteoclastic bone resorption and impaired osteoblastic bone formation. Traditional delivery of antiresorptive drugs lacks a specific biodistribution in the body and may cause adverse effects to the patients. In this study, the peptide BTRM is first synthesized consisting of the bone-targeting peptide Asp8 (BT) and the peptide derived from the amino acid sequences of RANK Motif2/3 (RM), two cytoplasmic RANK motifs (PVQEET 560–565 and PVQEQG 604–609 ) that have been reported to play an important role in osteoclastogenesis. Then, BTRM is conjugated on the plant virus-like nanoparticles (VNPs) obtained from cowpea chlorotic mottle viruses (CCMVs), forming the engineered plant viruses BTRM–VNPs. In vitro experiments demonstrate that BTRM–VNPs can effectively and safely inhibit osteoclast differentiation and function. Moreover, after injection into ovariectomized mice, BTRM–VNPs show excellent capability to target bone tissue and improve osteoporotic bone loss. Collectively, the findings may provide a novel and promising strategy in the treatment of osteoporotic defects via targeting bone tissue and regulating the function of RANK Motif2/3.
No takes yet. Share an insight, caveat, or question.
Li et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: